Video

Dr. Wakelee Discusses Dacomitinib in EGFR+ NSCLC

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses dacomitinib in patients with EGFR-positive non–small cell lung cancer.

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses dacomitinib in patients with EGFR-positive non—small cell lung cancer (NSCLC).

The data with dacomitinib have been very interesting, Wakelee says. In April 2018, the FDA granted dacomitinib a priority review for frontline treatment of patients with EGFR-positive locally advanced or metastatic NSCLC. This was based on findings from the phase III ARCHER 1050 trial, which compared dacomitinib with gefitinib (Iressa). Dacomitinib reduced the risk of disease progression or death by more than 40% and resulted in an average 6.5-month improvement in response duration compared with gefitinib as a first-line treatment.

Overall survival (OS) data were presented at the 2018 ASCO Annual Meeting. The median OS was 34.1 months in patients randomized to dacomitinib versus 26.8 months in those randomized to gefitinib. Wakelee says that challenges remain with toxicity. If this study had come out years ago before osimertinib (Tagrisso), then the question of whether to use dacomitinib in this population would not exist.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD